Skip to main content
SpringerLink
Log in

Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, and Fisher Jr C for the PROWESS study group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709

    CAS  PubMed  Google Scholar 

  2. Esmon CT (2001) Protein C anticoagulation pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med [Suppl 29]:S48–51

  3. Esmon CT (2000) Regulation of blood coagulation. Biochim Biophys Acta 1477:349–360

    Article  CAS  PubMed  Google Scholar 

  4. Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M (1999) Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 55:1568–1574

    Article  CAS  PubMed  Google Scholar 

  5. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG (1999) Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 81:589–593

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adult Intensive Care Unit, Academic Medical Center, Meibergdreef 9, 1105 AZ , Amsterdam, The Netherlands

    Anne Cornélie J. M. de Pont, Catherine S. C. Bouman, Evert de Jonge, Margreeth B. Vroom, Harry R. Büller & Marcel Levi

Authors
  1. Anne Cornélie J. M. de Pont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine S. C. Bouman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evert de Jonge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margreeth B. Vroom
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Harry R. Büller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcel Levi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Cornélie J. M. de Pont.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Pont, A.C.J.M., Bouman, C.S.C., de Jonge, E. et al. Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis. Intensive Care Med 29, 1205 (2003). https://doi.org/10.1007/s00134-003-1781-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-003-1781-4

Keywords

Search

Navigation